Physician profile
Douglas G Ebersole
NPI 1972575736
$373,418.81
in general payments reported to CMS, 2019-2025
19 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $73K · 2021: $94K · 2022: $16K · 2023: $27K · 2024: $33K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $23K · Travel and Lodging: $4,445 · Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,250.00 |
| Consulting Fee | $22,550.00 |
| Travel and Lodging | $4,444.87 |
| Food and Beverage | $2,443.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $196,781.83 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $165,366.57 | 2019-2025 | Watchman Access System, Versacross Access Solution, Watchman |
| Baylis Medical Company INC | $9,286.08 | 2019-2021 | |
| Penumbra, INC. | $956.93 | 2019-2020 | |
| Abbott Laboratories | $326.50 | 2019-2022 | |
| Medtronic, INC. | $167.40 | 2021-2023 | Corevalve Evolut R, Onyx Frontier |
| Abiomed | $148.49 | 2019-2025 | |
| Amgen INC. | $68.05 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $44.06 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.17 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $39.79 | 2021-2023 | Xarelto |
| Biosense Webster, INC. | $37.53 | 2025 | Nuvision Ice Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.19 | 2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $28.20 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $23.63 | 2023 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $19.40 | 2020 | |
| Pfizer INC. | $17.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.